Androgen Suppression Therapy Articles

Finasteride use has been associated with a reduced incidence of bladder cancer (BCa). However, the majority of studies have been conducted primarily in East Asian or Caucasian populations. Given differences in the incidence of BCa among racial/ethnic groups, it is important to determine whether the effect of finasteride use on BCa varies by race/ethnicity.

The purpose of this study was to summarize the existing evidence and develop a comprehensive systematic review of the impact of androgen suppression therapy (AST) on the incidence or clinical outcomes of bladder cancer.

Measurement of testosterone levels during androgen deprivation therapy (ADT) is broadly recommended, but how therapy should be altered in response to testosterone values during ADT remains controversial.

Bladder cancer demonstrates striking gender-based differences in incidence, with a role for androgens possibly implicated in the development and progression of the disease. Emerging preclinical and clinical evidence suggests that there may be a role for antiandrogen therapy in bladder cancer.